Brainstorm Cell Therapeutics (BCLI) Presents At 2020 BIO CEO & Investor Conference - Slideshow

Company Overview - Brainstorm Cell Therapeutics is a clinical-stage biotechnology company focused on autologous stem cell therapies for neurodegenerative diseases like ALS and Progressive MS[6] - The company highlights large addressable markets for ALS with 30000 patients in the US and 450000 worldwide, and for Progressive MS with 500000 patients in the US and 1250000 worldwide[6] - The company also mentions potential markets in Parkinson's Disease with 1000000 US patients and Huntington's Disease with 30000 US patients[23] Clinical Trials and Development - The company's lead product, NurOwn, is being evaluated in preclinical models for various neurodegenerative diseases[25] - A Phase 3 ALS trial is fully enrolled, with topline data expected in the second half of 2020[6, 37] - A Phase 2 Progressive MS trial is actively enrolling[6] NurOwn Mechanism and Data - NurOwn increases Treg Cells, as shown in Phase 1/2a trials and in-vitro studies[34] - Phase 2 clinical trial demographics show a balanced baseline between MSC-NTF (n=36) and Placebo (n=12) groups[45] - ALSFRS-R efficacy outcomes from a Phase 2 trial show a change from post-treatment to pre-treatment slope with MSC-NTF compared to placebo[48] - CSF Neurotrophic Factors increased post-treatment in NurOwn treated patients[50] Clinical Trial Status and Regulatory - The Phase 3 ALS clinical trial completed enrollment in October 2019, with a DSMB safety review conducted at the end of October 2019[74] - The company has an agreement with the FDA on potential regulatory pathways for approval in ALS as of February 2020[74] - The Phase 2 Progressive MS clinical trial IND was granted in December 2018, with the first subjects enrolled in March 2019[77]